Literature DB >> 18976293

Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation.

C Ashokkumar1, A Talukdar, Q Sun, B W Higgs, J Janosky, P Wilson, G Mazariegos, R Jaffe, A Demetris, J Dobberstein, K Soltys, G Bond, A W Thomson, A Zeevi, R Sindhi.   

Abstract

Antigen-specific T cells, which express CD154 rapidly, but remain untested in alloimmunity, were measured with flow cytometry in 16-h MLR of 58 identically-immunosuppressed children with liver transplantation (LTx), to identify Rejectors (who had experienced biopsy-proven rejection within 60 days posttransplantation). Thirty-one children were sampled once, cross-sectionally. Twenty-seven children were sampled longitudinally, pre-LTx, and at 1-60 and 61-200 days after LTx. Results were correlated with proliferative alloresponses measured by CFSE-dye dilution (n = 23), and CTLA4, a negative T-cell costimulator, which antagonizes CD154-mediated effects (n = 31). In cross-sectional observations, logistic regression and leave-one-out cross-validation identified donor-specific, CD154 + T-cytotoxic (Tc)-memory cells as best associated with rejection outcomes. In the longitudinal cohort, (1) the association between CD154 + Tc-memory cells and rejection outcomes was replicated with sensitivity/specificity 92.3%/84.6% for observations at 1-60 days, and (2) elevated pre-LTx CD154 + Tc-memory cell responses were associated with significantly increased incidence (p = 0.02) and hazard (HR = 7.355) of rejection in survival/proportional hazard analysis. CD154 expression correlated with proliferative alloresponses (r = 0.835, p = 7.1e-07), and inversely with CTLA4 expression of allospecific CD154 + Tc-memory cells (r =-0.706, p = 3.0e-05). Allospecific CD154 + T-helper-memory cells, not CD154 + Tc-memory, were inhibited by increasing Tacrolimus concentrations (p = 0.026). Collectively, allospecific CD154 + T cells provide an estimate of rejection risk in children with LTx.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976293      PMCID: PMC2997472          DOI: 10.1111/j.1600-6143.2008.02459.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  29 in total

Review 1.  The CD40/CD154 receptor/ligand dyad.

Authors:  U Schönbeck; P Libby
Journal:  Cell Mol Life Sci       Date:  2001-01       Impact factor: 9.261

2.  Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question.

Authors:  E J Suchin; P B Langmuir; E Palmer; M H Sayegh; A D Wells; L A Turka
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

3.  Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.

Authors:  Stephen P Perfetto; Pratip K Chattopadhyay; Laurie Lamoreaux; Richard Nguyen; David Ambrozak; Richard A Koup; Mario Roederer
Journal:  J Immunol Methods       Date:  2006-05-19       Impact factor: 2.303

Review 4.  The unfinished legacy of liver transplantation: emphasis on immunology.

Authors:  Thomas E Starzl; Fadi G Lakkis
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

5.  Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft.

Authors:  I Koyama; O Nadazdin; S Boskovic; T Ochiai; R N Smith; M Sykes; H Sogawa; T Murakami; T B Strom; R B Colvin; D H Sachs; G Benichou; A B Cosimi; T Kawai
Journal:  Am J Transplant       Date:  2007-02-07       Impact factor: 8.086

Review 6.  Tolerance assays: measuring the unknown.

Authors:  Kenneth A Newell; Christian P Larsen
Journal:  Transplantation       Date:  2006-06-15       Impact factor: 4.939

7.  CD4+ Th1 and CD8+ type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity.

Authors:  B Wang; H Fujisawa; L Zhuang; I Freed; B G Howell; S Shahid; G M Shivji; T W Mak; D N Sauder
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

8.  The kinetics of CD154 (CD40L) expression in peripheral blood mononuclear cells of healthy subjects in liver allograft recipients and X-linked hyper-IgM syndrome.

Authors:  A Bartlett; J McCall; R Ameratunga; S Munn
Journal:  Clin Transplant       Date:  2000-12       Impact factor: 2.863

9.  Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.

Authors:  N N Iwakoshi; J P Mordes; T G Markees; N E Phillips; A A Rossini; D L Greiner
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

10.  Persistent donor-specific alloreactivity may portend delayed liver rejection during drug minimization in children.

Authors:  Nandita Khera; Janine Janosky; Adriana Zeevi; George Mazariegos; Amadeo Marcos; Rakesh Sindhi
Journal:  Front Biosci       Date:  2007-01-01
View more
  29 in total

Review 1.  Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs.

Authors:  Alberto Sánchez-Fueyo; Terry B Strom
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

Review 2.  Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.

Authors:  Madhav C Menon; Barbara Murphy; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2017-01-06       Impact factor: 10.121

3.  A novel approach to measuring cell-mediated lympholysis using quantitative flow and imaging cytometry.

Authors:  G M La Muraglia; M J O'Neil; M L Madariaga; S G Michel; K S Mordecai; J S Allan; J C Madsen; I M Hanekamp; F I Preffer
Journal:  J Immunol Methods       Date:  2015-10-26       Impact factor: 2.303

Review 4.  Immune monitoring post liver transplant.

Authors:  Siddharth Sood; Adam G Testro
Journal:  World J Transplant       Date:  2014-03-24

Review 5.  Alloimmune T cells in transplantation.

Authors:  Susan DeWolf; Megan Sykes
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

6.  High-dose immunosuppressant alters the immunological status of New Zealand white rabbits following skin transplantation.

Authors:  Peilun Cheng; Liming Zhong; Zesheng Jiang; Yan Wang; Mingxin Pan; Y I Gao
Journal:  Exp Ther Med       Date:  2015-07-01       Impact factor: 2.447

7.  Lymphocyte activation markers may predict the presence of donor specific alloreactivity in pediatric living related liver transplant recipients.

Authors:  Udeme D Ekong; Xunrong Luo; Min Yu; Delli Wang; Stephen D Miller; Maurice R G O'Gorman
Journal:  Hum Immunol       Date:  2011-02-26       Impact factor: 2.850

8.  Increased expression of peripheral blood leukocyte genes implicate CD14+ tissue macrophages in cellular intestine allograft rejection.

Authors:  Chethan Ashokkumar; Mylarappa Ningappa; Sarangarajan Ranganathan; Brandon W Higgs; Qing Sun; Lori Schmitt; Sara Snyder; Jennifer Dobberstein; Maria Branca; Ronald Jaffe; Adriana Zeevi; Robert Squires; Feras Alissa; Benjamin Shneider; Kyle Soltys; Geoffrey Bond; Kareem Abu-Elmagd; Abhinav Humar; George Mazariegos; Hakon Hakonarson; Rakesh Sindhi
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

9.  Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children.

Authors:  Chethan Ashokkumar; Kyle Soltys; George Mazariegos; Geoffrey Bond; Brandon W Higgs; Mylarappa Ningappa; Qing Sun; Amanda Brown; Jaimie White; Samantha Levy; Tamara Fazzolare; Lisa Remaley; Katie Dirling; Patricia Harris; Tara Hartle; Pamela Kachmar; Megan Nicely; Lindsay OʼToole; Brittany Boehm; Nicole Jativa; Paula Stanley; Ronald Jaffe; Sarangarajan Ranganathan; Adriana Zeevi; Rakesh Sindhi
Journal:  Transplantation       Date:  2017-01       Impact factor: 4.939

10.  Proliferative alloresponse of T-cytotoxic cells identifies rejection-prone children with steroid-free liver transplantation.

Authors:  Chethan Ashokkumar; Qing Sun; Ankit Gupta; Brandon W Higgs; Tamara Fazzolare; Lisa Remaley; George Mazariegos; Kyle Soltys; Geoffrey Bond; Rakesh Sindhi
Journal:  Liver Transpl       Date:  2009-08       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.